A股異動 | 惠泰醫療漲10% 2022年預計淨利同比增加62%-79%
格隆匯1月20日丨惠泰醫療(688617.SH)漲10.13%,報354.62元,總市值236億元。惠泰醫療19日發佈2022年年度業績預吿,預計實現歸屬於母公司所有者的淨利潤為人民幣33,700萬元至37,300萬元,同比增加62.08%到79.39%。 公司採取系列措施,持續開展各類市場營銷活動,快速拓展醫院覆蓋率和滲透率,不斷擴大品牌知名度和影響力,積極拓展海外市場,2022年各產品線較上年同期均有不同程度增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.